KR102755938B1 - 변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도 - Google Patents

변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도 Download PDF

Info

Publication number
KR102755938B1
KR102755938B1 KR1020207020681A KR20207020681A KR102755938B1 KR 102755938 B1 KR102755938 B1 KR 102755938B1 KR 1020207020681 A KR1020207020681 A KR 1020207020681A KR 20207020681 A KR20207020681 A KR 20207020681A KR 102755938 B1 KR102755938 B1 KR 102755938B1
Authority
KR
South Korea
Prior art keywords
ttds
group
variant
xaa
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207020681A
Other languages
English (en)
Korean (ko)
Other versions
KR20200116085A (ko
Inventor
올리비에 두클로
스테판 일리아노
세르지오 말라
끌레르 미놀레띠-오쉐삐에
엘리사베타 비안키
라파엘레 인제니토
파올라 마고티
알레시아 산토프레테
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20200116085A publication Critical patent/KR20200116085A/ko
Application granted granted Critical
Publication of KR102755938B1 publication Critical patent/KR102755938B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207020681A 2018-01-31 2019-01-30 변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도 Active KR102755938B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
EP18305094.7 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (2)

Publication Number Publication Date
KR20200116085A KR20200116085A (ko) 2020-10-08
KR102755938B1 true KR102755938B1 (ko) 2025-01-20

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020681A Active KR102755938B1 (ko) 2018-01-31 2019-01-30 변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도

Country Status (29)

Country Link
US (3) US10961295B2 (enExample)
EP (1) EP3746467B1 (enExample)
JP (1) JP7295871B2 (enExample)
KR (1) KR102755938B1 (enExample)
CN (1) CN111770934B (enExample)
AR (1) AR114325A1 (enExample)
AU (1) AU2019214358B2 (enExample)
BR (1) BR112020014834A2 (enExample)
CA (1) CA3089657A1 (enExample)
CO (1) CO2020008308A2 (enExample)
DK (1) DK3746467T3 (enExample)
ES (1) ES3058633T3 (enExample)
FI (1) FI3746467T3 (enExample)
HR (1) HRP20260016T1 (enExample)
IL (2) IL316406A (enExample)
LT (1) LT3746467T (enExample)
MA (1) MA52994A (enExample)
MX (1) MX2020008096A (enExample)
MY (1) MY199821A (enExample)
NZ (1) NZ766762A (enExample)
PH (1) PH12020551118A1 (enExample)
PL (1) PL3746467T3 (enExample)
PT (1) PT3746467T (enExample)
RS (1) RS67606B1 (enExample)
SG (1) SG11202006903WA (enExample)
SI (1) SI3746467T1 (enExample)
TW (1) TWI763972B (enExample)
UY (1) UY38069A (enExample)
WO (1) WO2019149782A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177529A1 (en) 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
WO2015157829A1 (en) 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−２を調製する方法
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
JP2017513875A (ja) * 2014-04-22 2017-06-01 ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 分枝状アミノ酸プローブを有するペプチド類似体
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177529A1 (en) 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
WO2015157829A1 (en) 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides

Also Published As

Publication number Publication date
PT3746467T (pt) 2026-01-13
JP7295871B2 (ja) 2023-06-21
PL3746467T3 (pl) 2026-04-13
EP3746467B1 (en) 2025-10-08
IL276170B1 (en) 2024-11-01
HRP20260016T1 (hr) 2026-02-27
US20210292387A1 (en) 2021-09-23
JP2021512099A (ja) 2021-05-13
LT3746467T (lt) 2026-01-26
CA3089657A1 (en) 2019-08-08
WO2019149782A1 (en) 2019-08-08
US20240218042A1 (en) 2024-07-04
MY199821A (en) 2023-11-23
CO2020008308A2 (es) 2020-10-30
MX2020008096A (es) 2020-09-24
RS67606B1 (sr) 2026-01-30
BR112020014834A2 (pt) 2020-12-08
AR114325A1 (es) 2020-08-19
TWI763972B (zh) 2022-05-11
CN111770934B (zh) 2024-10-18
AU2019214358B2 (en) 2023-05-25
MA52994A (fr) 2021-05-05
TW201940505A (zh) 2019-10-16
CN111770934A (zh) 2020-10-13
KR20200116085A (ko) 2020-10-08
US20190233494A1 (en) 2019-08-01
UY38069A (es) 2019-08-30
SG11202006903WA (en) 2020-08-28
IL276170B2 (en) 2025-03-01
EP3746467A1 (en) 2020-12-09
SI3746467T1 (sl) 2026-02-27
IL316406A (en) 2024-12-01
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
PH12020551118A1 (en) 2021-07-05
ES3058633T3 (en) 2026-03-12
US10961295B2 (en) 2021-03-30
AU2019214358A1 (en) 2020-08-20
RU2020126210A (ru) 2022-02-28
IL276170A (en) 2020-09-30
US11725036B2 (en) 2023-08-15
DK3746467T3 (da) 2026-01-12

Similar Documents

Publication Publication Date Title
KR102755938B1 (ko) 변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도
KR102622642B1 (ko) 인크레틴 유사체 및 그의 용도
US10988523B2 (en) Modified lipidated Relaxin B chain peptides and their therapeutic use
US10988524B2 (en) Modified relaxin B chain peptides and their therapeutic use
US20250243255A1 (en) Crf2 receptor agonists and their use in therapy
KR20240153565A (ko) Crf2 수용체 작용제 및 치료법에서의 이의 용도
RU2804702C2 (ru) Модифицированные липидированные пептиды b-цепи релаксина и их терапевтическое применение
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
HK40112064A (zh) Crf2受体激动剂及其在治疗中的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200716

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220128

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240321

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241029

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250113

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250114

End annual number: 3

Start annual number: 1

PG1601 Publication of registration